Press releases

11 February, 2019

Regulatory

NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds

Lund, February 11, 2019 - NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company") (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the outcome of the preferential rights issue of shares ...

25 January, 2019

Regulatory

NeuroVive’s Board Members, Senior Executives and employees have subscribed to shares in the ongoing rights issue

In the current rights issue in NeuroVive, the Board, Senior Executives and employees have undertaken to subscribe for at least 1,778,995 shares equivalent to MSEK 2.4 which exceeds current holdings.

10 December, 2018

Regulatory

Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at 1 pm on Thursday 17 January 2019 at Medicon Village, Scheelevägen ...

10 December, 2018

Regulatory

NeuroVive resolves on a Rights issue of MSEK 123.8 for continued drug development, and new publication date of the 2018 Year End Report

Lund, Sweden, 10 December 2018 - NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "t ...

22 November, 2018

Regulatory

NeuroVive Pharmaceutical AB Interim report January – September 2018

KL1333 approved for phase I clinical trial

15 November, 2018

Regulatory

NeuroVive receives Vinnova funding to support development of NV354, a novel treatment for genetic mitochondrial disorders

Lund, 15 November, 2018- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the company has been awarded SEK 1.5 million as a first tranche of total SEK 5 million in ...

10 October, 2018

Regulatory

NeuroVive receives KL1333 clinical trial regulatory approval

Lund, Sweden, 10 October 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that it has received approval of its clinical trial application concerning a planned p ...

4 October, 2018

Regulatory

NeuroVive reports first NeuroSTAT clinical efficacy signal in TBI

Lund, Sweden, 4 October 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the successful completion of biomarker analyses of samples from its clinical study in se ...

6 September, 2018

Regulatory

NeuroVive receives positive FDA feedback on its NeuroSTAT TBI development plan

Lund, Sweden, 6 September 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced positive U.S. Food and Drug Administration (FDA) feedback on its NeuroSTAT clinical d ...

21 August, 2018

Regulatory

NeuroVive Pharmaceutical AB Interim report January – June 2018

NeuroVive out-licenses targeted LHON therapy to BridgeBio

18 June, 2018

Regulatory

NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma’s new subsidiary Fortify Therapeutics

Lund, Sweden and Palo Alto, Calif., June 18, 2018 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and BridgeBio Pharma today jointly announced that BridgeBio has entered into an ex ...

29 May, 2018

Regulatory

Information regarding trading of warrants issued by NeuroVive

THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR IN ANY OTHER JURISDICTION W ...